Research programme: hepatitis C therapeutics - Enanta

Drug Profile

Research programme: hepatitis C therapeutics - Enanta

Alternative Names: EP-CyP212; EP-NS5A25; HCV cyclophilin binders - Enanta; HCV NS5A protein inhibitors - Enanta/Novartis; HCV polymerase inhibitors - Enanta; Tetrazole type hepatitis C serine protease inhibitors - Enanta

Latest Information Update: 11 Feb 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Enanta Pharmaceuticals
  • Class Small molecules; Tetrazoles
  • Mechanism of Action Cyclophilin inhibitors; Hepatitis C protease inhibitors; Hepatitis C virus NS 5 protein inhibitors; Hepatitis C virus NS3 protein inhibitors; Polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Hepatitis C

Most Recent Events

  • 06 Feb 2015 Preclinical candidate selection is ongoing in USA
  • 01 Oct 2014 NS5A inhibitors are no longer licensed to Novartis
  • 17 May 2013 Preclinical development is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top